Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Intercure Ltd. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2022 001-40614 INTERCURE LTD. 85 Medinat ha-Yehudim Street Herzliya, 4676670, Israel Tel: +972 77 460 5012 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ On August 14, 2023, a Special General Meeting of Shareholders of InterCure Ltd. approved the proposal brought before the Company’ s shareholders at the meeting, in accordance with the majority required for the proposal. The said proposal was described in the Company’ s Notice of Special Meeting of Shareholders with respect to..."
07/24/2023 6-K Quarterly results
07/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2023 001-40614 INTERCURE LTD. 85 Medinat ha-Yehudim Street Herzliya, 4676670, Israel Tel: +972 77 460 5012 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Exhibit Index Exhibit No. Description 99.1 Press Release dated July 10, 2023 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.",
"InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE"
06/12/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2023 001-40614 INTERCURE LTD. 85 Medinat ha-Yehudim Street Herzliya, 4676670, Israel Tel: +972 77 460 5012 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Exhibit Index Exhibit No. Description 99.1 Press Release dated June 9, 2023 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.",
"NEW YORK, TORONTO, and HERZLIYA, Israel — June 9, 2023"
05/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 001-40614 INTERCURE LTD. 85 Medinat ha-Yehudim Street Herzliya, 4676670, Israel Tel: +972 77 460 5012 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Exhibit Index Exhibit No. Description 99.1 Press Release dated May 15, 2023 99.2 Management’ s Discussion and Analysis of Financial Condition and Results of Operations for the three-month period ended March 31, 2023 and 2022 99.3 Interim Condensed Consolidated Financial Statements for the period ended March 31, 2023 2 SIGNATURES...",
"InterCure Ltd.",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operations for the three-month period ended March 31, 2023 and 2022",
"Interim Condensed Consolidated Financial Statements for the period ended March 31, 2023 (Unaudited)"
05/01/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/26/2023 6-K Quarterly results
04/25/2023 6-K Quarterly results
04/20/2023 6-K Quarterly results
04/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2023 001-40614 INTERCURE LTD. 85 Medinat ha-Yehudim Street Herzliya, 4676670, Israel Tel: +972 77 460 5012 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Exhibit Index Exhibit No. Description 99.1 Press Release dated April 3, 2023 2 SIG...",
"InterCure Announces Reschedules 2022 Full Year Results Conference Call"
04/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2023 001-40614 INTERCURE LTD. 85 Medinat ha-Yehudim Street Herzliya, 4676670, Israel Tel: +972 77 460 5012 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Exhibit Index Exhibit No. Description 99.1 Press Release dated March 31, 2023 99.2...",
"InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results",
"Management’ s Discussion and Analysis for the year ended December 31, 2022",
"Consolidated Financial Statements as of December 31, 2022",
"Annual Information Form of the Company for the year ended December 31, 2022"
02/14/2023 6-K Quarterly results
02/01/2023 6-K Quarterly results
12/19/2022 6-K Quarterly results
12/05/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2022 001-40614 INTERCURE LTD. 85 Medinat ha-Yehudim Street Herzliya, 4676670, Israel Tel: +972 77 460 5012 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Exhibit Index Exhibit No. Description 99.1 Press Release dated December 5, 2022...",
"InterCure Ltd."
11/23/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2022 001-40614 INTERCURE LTD. 85 Medinat ha-Yehudim Street Herzliya, 4676670, Israel Tel: +972 77 460 5012 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Exhibit Index Exhibit No. Description 99.1 Press Release dated November 23, 202...",
"InterCure Ltd."
11/17/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2022 001-40614 INTERCURE LTD. 85 Medinat ha-Yehudim Street Herzliya, 4676670, Israel Tel: +972 77 460 5012 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Exhibit Index Exhibit No. Description 99.1 Press Release dated November 17, 202...",
"Organigram and InterCure Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies"
11/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2022 001-40614 INTERCURE LTD. 85 Medinat ha-Yehudim Street Herzliya, 4676670, Israel Tel: +972 77 460 5012 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Exhibit Index Exhibit No. Description 99.1 Unaudited Interim Consolidated Finan...",
"Unaudited Interim Consolidated Financial Statements for the Period Ended September 30, 2022",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operations for the Period Ended September 30, 2022",
"Form 52-109F2 – Certifications of Interim Filings",
"InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth."
08/18/2022 6-K Quarterly results
07/15/2022 6-K Quarterly results
06/27/2022 EFFECT Form EFFECT - Notice of Effectiveness:
06/23/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
05/24/2022 6-K Quarterly results
05/16/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
04/28/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2022 001-40614 INTERCURE LTD. 85 Medinat ha-Yehudim Street Herzliya, 4676670, Israel Tel: +972 77 460 5012 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Exhibit Index Exhibit No. Description 99.1 Annual Information Form of the Company ...",
"Annual Information Form of the Company for the year ended December 31, 2021",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operations for the years ended December 31, 2021 and 2020",
"Consolidated Financial Statements for the year ended December 31, 2021",
"InterCure Reports Record Breaking Q4 and 2021 Results – Exceeded Preliminary Results"
02/09/2022 6-K Quarterly results
01/04/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2022 001-40614 INTERCURE LTD. 85 Medinat ha-Yehudim Street Herzliya, 4676670, Israel Tel: +972 77 460 5012 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ____ Exhibit Index Exhibit No. Description 99.1 Press Release dated December 30, 2021...",
"INTERCURE LTD. Extraordinary General Meeting of Shareholders of Intercure Ltd. held on December 30, 2021 REPORT OF VOTING RESULTS"
12/03/2021 6-K Quarterly results
12/03/2021 6-K Quarterly results
11/17/2021 6-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2021 001-40614 INTERCURE LTD. 85 Medinat ha-Yehudim Street Herzliya, 4676670, Israel Tel: +972 77 460 5012 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Index Exhibit No. Description 99.1 Press Release dated November 1...",
"InterCure Expands Pharmacy Chain in Israel; Surpasses One-Ton Medical Cannabis Products Dispensed Per Month",
"InterCure Announces Record Third Quarter Financial Results with 3 Times YoY Revenue Growth and 36% QoQ Growth",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operations for the three and nine-month periods ended September 30, 2021 and 2020",
"Interim Condensed Consolidated Financial Statements for the period ended September 30, 2021 (Unaudited)"
10/25/2021 6-K Quarterly results
10/05/2021 EFFECT Form EFFECT - Notice of Effectiveness:
10/04/2021 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy